Loading…
for educational and safety purposes
Fasoracetam and Coluracetam both come up in the same conversations; they overlap on Acetylcholine. Fasoracetam: Fasoracetam is a racetam-class nootropic that acts on the glutamatergic and GABAergic systems; with repeated administration it up-regulates GABA-B and metabotropic glutamate (mGluR) receptors. Coluracetam: Coluracetam has the most distinctive proposed mechanism in the racetam family.
Fasoracetam is a racetam-class nootropic that acts on the glutamatergic and GABAergic systems; with repeated administration it up-regulates GABA-B and metabotropic glutamate (mGluR) receptors. It is one of relatively few racetams to have reached controlled human trials, having been evaluated in adolescents with attention-deficit hyperactivity disorder who carry variants in genes governing mGluR signaling. It remains an investigational compound and is not an approved medicine.
Coluracetam has the most distinctive proposed mechanism in the racetam family. Rather than acting at a receptor, it was designed to raise the rate at which neurons take up choline, the raw material the brain uses to build acetylcholine. Mitsubishi developed it in Japan in the 1990s as an Alzheimer's candidate, and it was later carried into depression research and through a completed 115-person trial. Readers who use it describe sharper focus and, unusually for a nootropic, changes in visual vividness. The evidence for the mechanism is narrower than the reputation: the choline-uptake effect was shown in animals whose cholinergic neurons had been deliberately lesioned first and not in normal tissue, and an independent group at Pfizer testing the same transporter across four separate methods found no effect at all. That lesion-dependence is itself worth understanding, because it would predict a quieter effect in a healthy brain rather than none. No human trial has yet reported a cognitive result; the 2009 study completed without publishing its outcomes.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
upregulates
enhances
agonist
enhances
Increase, again restricted to lesioned tissue. Reversed the AF64A-induced fall in potassium-evoked ACh release from hippocampal synaptosomes and slices, and restored basal hippocampal ACh by in vivo microdialysis. In mice, only chronic dosing restored hippocampal ACh; acute dosing did nothing.
No inhibition. This is affirmative negative evidence from a direct assay, and it distinguishes coluracetam from donepezil, tacrine and the rest of the cholinesterase-inhibitor class.
strengthens
Proposed positive modulator. Reported to raise the Vmax of high-affinity choline uptake about 1.6-fold and the Bmax of [3H]-hemicholinium-3 binding about 1.7-fold, interpreted as driving more transporter to the synaptic membrane rather than changing transporter affinity. Critically, the effect is reported ONLY in cholinergically lesioned tissue and is absent in normal tissue.
No binding. Neither [3H]-quinuclidinyl benzilate (general muscarinic) nor [3H]-pirenzepine (M1-preferring) binding was affected, so the compound is not a muscarinic ligand.
mild potentiation
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Fasoracetam is currently listed by more trusted vendors (2), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.